I haven't seen one long lose faith... But thanks for your contribution to this board. The title to this thread is why I want the price to go down so I can buy more shares (or other ulterior motive). There is no other reason for you to be here.
Exactly... Inquiring minds want to know. I see some stupidity, but nothing illegal.
Yes this is a good thing. They know the science and they are targeting the right diseases. Like I said, I am a scientist that studies immunology and I am invested in this company.
When INO becomes big enough, it would be interesting if they can try to do a preventative trial with the hTERT vaccine to see if less people develop cancers (of any type) that were vaccinated than those that were not vaccinated. Even a 10% reduction in cancers would be a big deal.
Regrose- I pulled up my thread where Daddy asked a question about the hTERT vaccine. I gave a very detailed explanation there. But to answer your question here:
1) hTERT is either upregulated (increased protein expression), or has an activating mutation causing increased activity, or can actually downregulated in ~85% of tumors. Most of these tumors have either up regulation or an activating mutation.
2) Just because it is upregulated or activated does not mean it is doing anything for tumor progression
3) For Cervical cancer: Cervical cancer is caused by oncogenic proteins present in high risk HPV strains. These proteins cause cell cycle and checkpoint proteins in the host cells to proliferate, regardless of external signals (usually external signals like growth factors are required for them to proliferate). They cause cells to proliferate, and when they proliferate uncontrolled, they acquire mutations which lead to the development of immortalized cells and hence cancers. hTERT may or may not be mutated in cervical cancer, but the cause of the cervical cancer is the infection with HPV. Whether hTERT is mutated or not does not matter for the development of cervical cancer as cervical cancer would develop whether hTERT is mutated or not.
4) Here's where it matters. If you have an hTERT mutation in cervical cancer, and the mutant hTERT is being expressed (mutated protein is being produced), then that protein can still be targeted by a vaccine to help cure the cervical cancer (even if it is not the cause of the cancer). If the mutated hTERT protein is not being expressed, or if the hTERT protein is normal (not mutated) then you really can't target it, because the vaccine wouldn't work (if the protein isn't being expressed by the cancer cells- T cells won't recognize the cancer. If the protein is normal/not mutated, you don't want to target it because you may cause autoimmunity to hTERT expressing cells, causing bone marrow failure.
Hope this helps.
Or LJPC or OXGN. He tweeted to his followers that OXGN was worse than CNDO... How did that work out for them after hours yesterday? Don't you worry. He will frantically and endlessly make poop up about how the stats or the numbers don't add up in one of the company's 14 figures and say, see I told you so. So far he is what, 1 for 4 this year.
He was right on CHTP. Gotta give him credit for that. 4 years of poly sci education teaches you a thing or two about biotech. But a thing or two isn't going to cut it, unless you work for a jerk off like Cramer, who doesn't care about anyone but himself.
Did you look at the website? It looks like shorts were holding on a longer term basis before the funding was announced.
there is a web site called stock analytics without a space. Check out AMBS and ARIA over the last 3 days on this site. Shorts covering like crazy in both stocks. The only reason I bring ARIA to this board too is because the pattern over the past few weeks of both stocks has been very similar, as well as the short covering. I wonder if Zarc is the only short left here... I think both stocks are going to have huge moves this week. If news hits, they are going way up. The short squeeze on both won't be as huge, but the moves up will be more easily sustainable.
I bought once at 0.13. Went up to .22, then back down to 14 cents, sold at 0.16 because I got scared. Bought back in at 0.22. Sold enough shares to recoup my initial investment at .56 ($1500). Its all free money here. Gonna ride it until it stops going up. Right now this stock has cost me nothing. Up $4500 of virtual money from zero dollars cost to me right now. I really wish I didn't freak out at 16 cents. I initially had 2000 at 0.13. would have about 8000 now. Oh well.
Sorry, typo. Where I say "INO lacks a littlle in the antigen component" it should say "INO lacks a littlle in the adjuvant component"
I've said it before on both boards (ONCS and INO). The technology is the same but the science is not. ONCS does not a cancer vaccine. It has a cancer adjuvant. IL-12 is a protein your own body makes during immune responses. ONCS plasmid is the IL-12 plasmid, so it makes your cells that get transfected with the plasmid make IL-12. This is not a specific treatment for melanoma or merkel cell carcinoma. It is a non-specific immune adjuvant. Check out Ziopharm for another way to get IL-12 into cells of interest. They use an adenoviral vector instead of electroporation to get the IL-12 plasmid into cells. It is controlled with an intrexon based on- off switch to control the level of IL-12. Same end result for ZIOP and ONCS. More IL-12.
Inovio uses actual DNA encoding antigens or protein components (of viruses, bacteria, or mutated self/cancer proteins) with electroporation to produce the DNA vaccine. Although the DNA vaccine itself activates the innate immune system by activating intracellular DNA sensors, INO lacks a littlle in the antigen component (hence, why they recently started adding a IL-33 plasmid.
INO success does not equal ONCS success. Similarly, ONCS success does not equal INO success. I am not saying either will fail. But so many people think success by INO validates ONCS, but that is not true. Success in ZIOP validates ONCS and vice versa.
Also PD-1 trials do not validate INO or ONCS. The PD-1 inhibitor takes off the natural brake on T cells. IL-12 activates T cells to become T helper 1 cells and cytotoxic T cells, as well as activates NK cells. But the more IL-12 you have, and the more immune activation you have, the more PD-1 gets induced to put more brakes on the system. That's why I really like ONCS combining their IL-12 with a PD-1 inhibitor.
If either ONCS or INO fail their next stage in the clinical trial, it is not over by any stretch of the imagination (ONCS can add antigen, INO can add adjuvant). If they succeed tho, its just the beginning
Please please please bring it. If this drops to 5 cents, I will pick up another truck load of shares. If you don't do that as well with all your bashing, what is your point of being here? Will you stop bashing then?when it dropped to 7.5 cents, I didn't have any money available . Now I do.
Wow. That was a quick dislike. Can I get another? Sorry for putting your undies in a bunch shorty...
Type in "VGX Animal Health DNA Vaccine for Dogs Could Reduce Tumor Growth and Increase Survival"
Its the dog version of the TERT vaccine. Shrinks tumors in dogs
What about ones that cause heart failure? Like imatinib and sunitinib? They seem to be doing just fine and staying on the market. A little reversible blood clotting is nothing two of these couldn't fix. But please don't call me in the morning.
Remember, this rumor was started by the Street. The same guys who stomped the rumor the first time... Hmmm... Does Cramer have an agenda? I wonder.
Its going to 10-12 just with the rumor. But you're right. Double from here depending on partner news.
See my post in regards to farmer John's thread.
Thewhole field is validated by ISIS. This is catching up to the potential valuation.
It still may fail. But the tech is valid.